Glioma Diagnosis and Treatment Market Research Report – Forecast to 2027

Glioma Diagnosis and Treatment Market: By Type (Primary, Secondary) Diagnosis (CT, MRI) Treatment (Surgery, Chemotherapy), Grade (Low, High, Recurrent), Location (Supratentorial, Infratentorial), End-User (Hospitals & Clinics) – Global Forecast Till 2027

ID: MRFR/Pharma/4421-HCR | February 2021 | Region: Global | 100 pages

Market Scenario


A glioma is a type of tumor that originates in the brain and is also known as a primary brain tumor. There are numerous types of gliomas which are entitled based on the origin of the cell type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma. Nearly 33 percent of all brain tumors are gliomas. These originate in glial cells surrounding the neurons in the brain. According to the American Brain Tumor Association, more than 79,000 new cases of primary brain tumors were diagnosed in 2017 with 24.7% of those being gliomas.


Astrocytoma is the most common types of glioma diagnosed worldwide, as more than 30% of all the diagnosed cases with brain tumors are astrocytoma. These types of tumors are not curable as they spread easily through normal brain tissue. The American Brain Tumor Association has evaluated that around 7% of all the primary brain tumors represent astrocytoma.


The expanding market for the treatment of brain cancer-associated symptoms, the increasing prevalence of brain cancer, and innovations in drug delivery to brain cancer cells are some of the key factors augmenting the demand in the global glioma diagnosis and treatment market. Furthermore, the introduction of novel therapies coupled with various organizations generating awareness and increasing geriatric population are factors driving the growth of the global glioma diagnosis and treatment market.


Global Glioma Diagnosis and Treatment market is expected to grow at a CAGR of approximately 10.1% during the forecast period, 2017–2023.


Intended Audience



  • Glioma Drug Manufacturers and Suppliers

  • Glioma Treatment Providers

  • Imaging Device Manufacturers

  • Hospitals and Clinics

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities

  • Market Research and Consulting Service Providers

  • Potential Investors


Figure 1: - Global Glioma Diagnosis and Treatment Market Share, by Region


 Glioma Diagnosis and Treatment Market


Segmentation


The glioma diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, grade, location, and end-user.


On the basis of type, the global glioma diagnosis and treatment market is segmented into primary tumors and secondary tumors. Primary tumors are divided into ependymomas, astrocytoma, oligodendrogliomas, brainstem glioma, optic nerve glioma, mixed gliomas, and others.


The ependymomas segment is divided into subependymomas (grade i), myxopapillary ependymomas (grade i), ependymomas (grade ii), and anaplastic ependymomas (grade iii). The astrocytomas segment is divided into anaplastic astrocytomas, glioblastoma multiforme, and benign astrocytomas. The optic nerve glioma segment is divided into malignant optic nerve glioma and benign optic nerve glioma. The mixed gliomas are divided into oligoastrocytomas and others.


On the basis of diagnosis, the global glioma diagnosis and treatment market is classified into neurological exam, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scan, biopsy, molecular testing, Electroencephalography (EEG), and others.


On the basis of treatment, the global glioma diagnosis and treatment market is classified into surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. Furthermore, the surgery is further categorized into open surgery and minimally invasive surgery.


On the basis of grade, the global glioma diagnosis and treatment market is segmented into low-grade gliomas, high-grade gliomas, and recurrent high-grade glioma.


On the basis of location, the global glioma diagnosis and treatment market is segmented into supratentorial and infratentorial.


On the basis of end-user, the global glioma diagnosis and treatment market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.


Research Methodology


 Glioma Diagnosis and Treatment Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis


The global glioma diagnosis and treatment market consist of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of brain tumor, rising awareness among people, and increasing healthcare expenditure. Brain tumor is the third most common types of cancer in adults in North America. According to the North American Brain Tumor Coalition over 44,500 people in the U.S. were diagnosed with a primary tumor in the brain in 2014. Thus, the increasing incidences of primary brain tumor support the growth of the malignant glioma treatment in North America.  


Asia Pacific is estimated to be the most lucrative market for gliomas due to the increasing occurrence of brain tumors in Asia Pacific countries such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.


Growing medical tourism and prevalence of metastatic tumors that require surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of brain tumors are similarly supporting the growth of this market.


Key Players


Some of the key players in the global glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.), and others.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   10.1% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, Grade, Location and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.)
  Key Market Opportunities   Introduction of novel therapies coupled with Rising awareness
  Key Market Drivers   Increasing prevalence of brain cancer and innovations in drug delivery to brain cancer cells


Frequently Asked Questions (FAQ) :


A glioma is a type of tumor that originates in the brain.

Glioma Diagnosis And Treatment Market is expected to exhibit a strong 10.1% CAGR over the forecast period from 2020 to 2027.

Growing emphasis on cancer treatment from healthcare bodies is likely to be a major driver for the market.

Americas hold the dominant share in the Global Glioma Diagnosis And Treatment Market.

Leading players in the Glioma Diagnosis And Treatment Market include Thermo Fisher Scientific, Emcure Pharmaceuticals, and Sigma-Aldrich, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Glioma Diagnosis and Treatment Market, by Type

6.1 Introduction

6.2 Primary Tumor

6.2.1 Market Estimates & Forecast, 2020–2027

6.2.2 Ependymomas

6.2.2.1 Market Estimates & Forecast, 2020–2027

6.2.2.2 Subependymomas (grade i)

6.2.2.2.1 Market Estimates & Forecast, 2020–2027

6.2.2.3 Myxopapillary Ependymomas (grade i)

6.2.2.3.1 Market Estimates & Forecast, 2020–2027

6.2.2.4 Ependymomas (grade ii)

6.2.2.4.1 Market Estimates & Forecast, 2020–2027

6.2.2.5 Anaplastic Ependymomas (grade iii)

6.2.2.5.1 Market Estimates & Forecast, 2020–2027

6.2.3 Astrocytomas

6.2.3.1 Market Estimates & Forecast, 2020–2027

6.2.3.2 Anaplastic Astrocytomas

6.2.3.2.1 Market Estimates & Forecast, 2020–2027

6.2.3.3 Glioblastoma Multiforme

6.2.3.3.1 Market Estimates & Forecast, 2020–2027

6.2.3.4 Benign Astrocytomas

6.2.3.4.1 Market Estimates & Forecast, 2020–2027

6.2.4 Oligodendrogliomas

6.2.4.1 Market Estimates & Forecast, 2020–2027

6.2.5 Brainstem Glioma

6.2.5.1 Market Estimates & Forecast, 2020–2027

6.2.6 Optic Nerve Glioma

6.2.6.1 Market Estimates & Forecast, 2020–2027

6.2.6.2 Malignant Optic Nerve Glioma

6.2.6.2.1 Market Estimates & Forecast, 2020–2027

6.2.6.3 Benign Optic Nerve Glioma

6.2.6.3.1 Market Estimates & Forecast, 2020–2027

6.2.7 Mixed Gliomas

6.2.7.1 Market Estimates & Forecast, 2020–2027

6.2.7.2 Oligoastrocytomas

6.2.7.2.1 Market Estimates & Forecast, 2020–2027

6.2.7.3 Others

6.3 Secondary Tumor

6.3.1 Market Estimates & Forecast, 2020–2027

Chapter 7. Global Glioma Diagnosis and Treatment Market, by Diagnosis

7.1 Introduction

7.2 Neurological Exam

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Computed Tomography (CT) scan

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Magnetic Resonance Imaging (MRI)

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 Radionuclide Imaging

7.5.1 Market Estimates & Forecast, 2020–2027

7.6 Position Emission Tomography (PET) Scan

7.6.1 Market Estimates & Forecast, 2020–2027

7.7 Biopsy

7.7.1 Market Estimates & Forecast, 2020–2027

7.8 Molecular Testing

7.8.1 Market Estimates & Forecast, 2020–2027

7.9 Electroencephalography (EEG)

7.9.1 Market Estimates & Forecast, 2020–2027

7.10 Others

Chapter 8. Global Glioma Diagnosis and Treatment Market, by Treatment

8.1 Introduction

8.2 Surgery

8.2.1 Market Estimates & Forecast, 2020–2027

8.2.2 Open Heart Surgery

8.2.2.1 Market Estimates & Forecast, 2020–2027

8.2.3 Minimal Invasive Surgery

8.2.3.1 Market Estimates & Forecast, 2020–2027

8.3 Chemotherapy

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Radiation Therapy

8.4.1 Market Estimates & Forecast, 2020–2027

8.5 Immunotherapy

8.5.1 Market Estimates & Forecast, 2020–2027

8.6 Targeted Therapy

8.6.1 Market Estimates & Forecast, 2020–2027

Chapter 9. Global Glioma Diagnosis and Treatment Market, by Grade

9.1 Introduction

9.2 Low-Grade Gliomas

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 High-Grade Gliomas

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Recurrent High-Grade Glioma

9.4.1 Market Estimates & Forecast, 2020–2027

Chapter 10. Global Glioma Diagnosis and Treatment Market, by Location

10.1 Introduction

10.2 Supratentorial

10.2.1 Market Estimates & Forecast, 2020–2027

10.3 Infratentorial

10.3.1 Market Estimates & Forecast, 2020–2027

Chapter 11. Global Glioma Diagnosis and Treatment Market, by End-U.S.er

11.1 Introduction

11.2 Hospitals & Clinics

11.2.1 Market Estimates & Forecast, 2020–2027

11.3 Diagnostic Centers

11.3.1 Market Estimates & Forecast, 2020–2027

11.4 Medical Research Centers

11.4.1 Market Estimates & Forecast, 2020–2027

11.5 Others

Chapter .12 Global Glioma Diagnosis and Treatment Market, by Region

12.1 Introduction

12.2 Americas

12.2.1 North America

12.2.1.1 U.S.

12.2.1.1 Canada

12.2.2 South America

12.3 Europe

12.3.1 Western Europe

12.3.1.1 Germany

12.3.1.2 France

12.3.1.3 Italy

12.3.1.4 Spain

12.3.1.5 U.K.

12.3.1.6 Rest of Western Europe

12.3.2 Eastern Europe

12.4 Asia Pacific

12.4.1 Japan

12.4.2 China

12.4.3 India

12.4.4 Australia

12.4.5 Republic of Korea

12.4.6 Rest of Asia Pacific

12.5 The Middle East & Africa

12.5.1 United Arab Emirates

12.5.2 Saudi Arabia

12.5.3 Oman

12.5.4 Kuwait

12.5.5 Qatar

12.5.6 Rest of the Middle East & Africa

Chapter 13 Company Landscape

13.1 Introduction

13.2 Market Share Analysis

13.3 Key Development & Strategies

13.3.1 Key Developments

Chapter 14 Company Profiles

14.1 Thermo Fisher Scientific Inc.

14.1.1 Company Overview

14.1.2 Product Overview

14.1.3 Financials

14.1.4 SWOT Analysis

14.2 Emcure Pharmaceuticals Ltd.

14.2.1 Company Overview

14.2.2 Product Overview

14.2.3 Financial Overview

14.2.4 Key Developments

14.2.5 SWOT Analysis

14.3 Pfizer Inc.

14.3.1 Company Overview

14.3.2 Product Overview

14.3.3 Financial Overview

14.3.4 Key Development

14.3.5 SWOT Analysis

14.4 Novartis International AG

14.4.1 Company Overview

14.4.2 Product/Business Segment Overview

14.4.3 Financial Overview

14.4.4 Key Development

14.4.5 SWOT Analysis

14.5 Teva Pharmaceutical Industries Ltd.

14.5.1 Company Overview

14.5.2 Product Overview

14.5.3 Financial overview

14.5.4 Key Developments

14.6 Shimadzu Corporation

14.6.1 Company Overview

14.6.2 Product Overview

14.6.3 Financial Overview

14.6.4 Key Developments

14.7 GE Healthcare

14.7.1 Overview

14.7.2 Product Overview

14.7.3 Financials

14.7.4 Key Developments

14.7.5 SWOT Analysis

14.8 Siemens Healthineers

14.8.1 Company Overview

14.8.2 Product/Business Segment Overview

14.8.3 Financial Overview

14.8.4 Key Development

14.8.5 SWOT Analysis

14.9 Toshiba Medical Systems Corporation

14.9.1 Company Overview

14.9.2 Product Overview

14.9.3 Financial overview

14.9.4 Key Developments

14.10 Others

Chapter 15 MRFR Conclusion

15.1 Key Findings

15.1.1 From CEO’s View Point

15.1.2 Unmet Needs of the Market

15.2 Key Companies to Watch

15.3 Prediction of Pharmaceutical Industry

Chapter 16 Appendix

LIST OF TABLES

Table 1 Glioma Diagnosis and Treatment Industry Synopsis, 2020–2027

Table 2 Glioma Diagnosis and Treatment Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Glioma Diagnosis and Treatment Market, by Region, 2020–2027, (USD Million)

Table 4 Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 5 Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 7 North America glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 8 North America Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 9 North America Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 10 U.S. Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 11 U.S. Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 12 U.S. Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 13 Canada Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 14 Canada Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 15 Canada Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 16 South America Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 17 South America Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 South America Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 19 Europe Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 20 Europe Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 21 Europe Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 22 Western Europe Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 23 Western Europe Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 24 Western Europe Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 25 Eastern Europe Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 26 Eastern Europe Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 27 Eastern Europe Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 28 Asia Pacific Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 29 Asia Pacific Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Asia Pacific Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 31 Middle East & Africa Glioma Diagnosis and Treatment Market, by Type, 2020–2027, (USD Million)

Table 32 Middle East & Africa Glioma Diagnosis and Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 33 Middle East & Africa Glioma Diagnosis and Treatment Market, by Treatment, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Glioma Diagnosis and Treatment Market

Figure 3 Segmentation Market Dynamics for Glioma Diagnosis and Treatment Market

Figure 4 Global Glioma Diagnosis and Treatment Market Share, by Type 2020

Figure 5 Global Glioma Diagnosis and Treatment Market Share, by Diagnosis 2020

Figure 6 Global Glioma Diagnosis and Treatment Market Share, by Treatment, 2020

Figure 7 Global Glioma Diagnosis and Treatment Market Share, by Region, 2020

Figure 8 North America Glioma Diagnosis and Treatment Market Share, by Country, 2020

Figure 9 Europe Glioma Diagnosis and Treatment Market Share, by Country, 2020

Figure 10 Asia Pacific Glioma Diagnosis and Treatment Market Share, by Country, 2020

Figure 11 Middle East & Africa Glioma Diagnosis and Treatment Market Share, by Country, 2020

Figure 12 Global Glioma Diagnosis and Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 THERMO FISHER SCIENTIFIC INC.: Key Financials

Figure 14 THERMO FISHER SCIENTIFIC INC.: Segmental Revenue

Figure 15 THERMO FISHER SCIENTIFIC INC.: Geographical Revenue

Figure 16 Emcure Pharmaceuticals Ltd.: Key Financials

Figure 17 Emcure Pharmaceuticals Ltd.: Segmental Revenue

Figure 18 Emcure Pharmaceuticals Ltd.: Geographical Revenue

Figure 19 Pfizer Inc.: Key Financials

Figure 20 Pfizer Inc.: Segmental Revenue

Figure 21 Pfizer Inc.: Geographical Revenue

Figure 22 Novartis International AG: Key Financials

Figure 23 Novartis International AG: Segmental Revenue

Figure 24 Novartis International AG: Geographical Revenue

Figure 25 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 26 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 27 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 28 Shimadzu Corporation.: Key Financials

Figure 29 Shimadzu Corporation: Segmental Revenue

Figure 30 Shimadzu Corporation: Geographical Revenue

Figure 31 GE Healthcare: Key Financials

Figure 32 GE Healthcare: Segmental Revenue

Figure 33 GE Healthcare: Geographical Revenue

Figure 34 Siemens Healthineers: Key Financials

Figure 35 Siemens Healthineers: Segmental Revenue

Figure 36 Siemens Healthineers: Geographical Revenue

Figure 37 Toshiba Medical Systems Corporation: Key Financials

Figure 38 Toshiba Medical Systems Corporation: Segmental Revenue

Figure 39 Toshiba Medical Systems Corporation: Geographical Revenue